InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,868.40
(
-0.79%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
87.07
(
-0.18%
)
Bitcoin
64,195.03
(
-0.13%
)
Post# of 251590
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

tony111

Send PM Follow Ignore
Followers 10
Posts 1064
Boards Moderated 0
Alias Born 11/24/2007

tony111

Re: jq1234 post# 180657

Wednesday, 07/23/2014 7:29:16 PM

Wednesday, July 23, 2014 7:29:16 PM

Post# of 251590
Sure pertuzumab seems to suggest inhibiting other family of EGF and dimerization might be important. However, If I recall correctly 543 was not as potent as 380 in clinical trials due to tolerability issues. Targeting EGF-1 might be an added benefit but it also reduces MTD and reduces HER-2 inhibition. ONTY is running a combo of 380 with herceptin and TMD-1. We should see in 2-3 years if I am wrong.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up